Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark will ...

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

CVS said Caremark will offer Wegovy at "a more affordable ... investors worried about direct competition in the market between Zepbound and Wegovy. Lilly executives remained unfazed about the ...

who are more likely to stick with Caremark's standard formularies. Larger companies covering more patients often use customized formularies, meaning they can still decide to include Zepbound.

Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...